Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)
October 23, 2013 updated by: W.J. Pasman, TNO
A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2).
In the present study human recombinant placental alkaline phosphatase (hRESCAP) will be investigated.
Alkaline Phosphatase is naturally present in the body and reported to use lipopolysaccharde (LPS, bacterial endotoxins) and extracellular nucleotides leaking from damaged and ischemic cells as physiological substrates.
The LPS-substrate prevalence makes alkaline phosphatase an interesting novel therapeutic agent in the treatment of LPS-mediated diseases.
A bovine homologue of this protein (bovine intestinal alkaline phosphatase, BIAP) has previously been investigated for treatment of acute inflammatory responses such as sepsis, and was shown to be safe in humans.
hRESCAP, which will be investigated in the current study, is expected to have a longer half-life in humans than the previously investigated BIAP, due to the fact that it is more sialylated.
The possibility to increase the t1/2 to days instead of minutes enables treatment of chronic diseases.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In the current study the peak plasma concentration (pharmacokinetics/elimination) of [14C]-labelled hRESCAP in healthy volunteers will be investigated at increasing single doses (up to anticipated therapeutic dose), with a microdose (≤30 nmol) as a safe starting dose.
- Part 1: To assess the peak plasma concentration of a single microdose (≤30 nmol) of a recombinant human protein (hRESCAP), administered intravenously, as a suitable technique to predict the pharmacokinetics in humans at pharmacologically relevant doses;
- Part 2: To determine the safety and tolerability of single dose of hRESCAP up to 5300 µg in healthy male volunteers administered intravenously;
- To determine the peak plasma concentration of hRESCAP in healthy male volunteers within a pharmacologically relevant dose-range and compare this with BIAP pharmacokinetics with emphasis on half-life (t1/2).
Study Type
Interventional
Enrollment (Anticipated)
4
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South-Holland
-
Leiden, South-Holland, Netherlands, 2333CL
- Centre For Human Drug Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects, 18 - 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, and urinalysis;
- Body mass index (BMI) between 18 and 30 kg/m2, inclusive;
- Ability to communicate well with the investigator in the Dutch language;
- Able to participate and willing to give written informed consent and to comply with the study restrictions;
- Venous access sufficient to allow blood sampling as per protocol.
Exclusion Criteria:
- Any clinically significant abnormality as determined by medical history taking and physical examinations obtained during the screening visit that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
- History of a surgical event that may significantly affect the study outcome;
- History of allergy or other inflammatory indications;
- History of asthma or other inflammatory disease;
- Use of prescription medications, over the counter medications, vitamin, herbal and dietary supplements within 21 days prior to study drug administrations, or less than 5 half-lives, whichever is longer, and during the course of the study.
- Alkaline Phosphatase levels in plasma of < 30 IU/L or > 115 IU/L;
- Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings at screening that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
- Participation in an investigational drug, food (ingredients) or device study within 3 months prior to screening or more than 4 times in the past year;
- Any psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol;
- History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption > 28 units/week);
- Reported unexplained weight loss or weight gain of > 2 kg in the month prior to screening;
- Positive test results for Hepatitis B, Hepatitis C or HIV;
- Donation of blood within 3 months prior to screening or donation of plasma within 14 days prior to screening;
- Not having a general practitioner;
- Not willing to accept information transfer which concerns participation in the study, or information regarding health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner;
- Not willing to give permission to have the general practitioner to be notified upon participation in this study;
- Prior participation in part 1 is not allowed for subjects participating in part 2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 14C-hRESCAP
Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
|
one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
Other Names:
|
|
Placebo Comparator: saline
Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
|
|
|
Active Comparator: Microdose
Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
|
one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the peak plasma concentration of hRESCAP after microdose administration of hRESCAP
Time Frame: 35 days
|
After administration of hRESCAP intravenously, blood will be withdrawn of the subjects frequently for in total 35 days (five times the anticipated half-life period of one week).
|
35 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In the ascending dose study increased dosages of of hRESCAP will be supplied till finally the therapeutic dose.
Time Frame: Two weeks (based upon time phrame of micodose section of the study)
|
In three subjects a low, medium and high dose of hRESCAP will be administered and a control saline administration in one subject.
The peak plasma concentration of hRESCAP response of different dosages will be useful for treatment evaluation.
The administration of the different dosages supplied is one week apart for safety reasons.
|
Two weeks (based upon time phrame of micodose section of the study)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Koos Burggraaf, MD, PhD, CHDR
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
July 1, 2013
Study Completion (Actual)
October 1, 2013
Study Registration Dates
First Submitted
June 18, 2013
First Submitted That Met QC Criteria
June 27, 2013
First Posted (Estimate)
June 28, 2013
Study Record Updates
Last Update Posted (Estimate)
October 24, 2013
Last Update Submitted That Met QC Criteria
October 23, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CHDR1220
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.